# US 8,771,685 B2 · Anti-BV8 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,685 B2
- Document ID: US8771685B2
- Status: Granted
- Kind: B2
- Application number: 12/975,784
- Filed: 2010-12-22
- Published: 2012-01-19
- Granted: 2014-07-08
- Earliest claimed: 2009-12-23
- Assignees: F. Hoffmann-La Roche AG
- Applicants: Xiumin Wu; Yan Wu; Lanlan Yu; Napoleone Ferrara; Wei-Ching Liang; Yu-Ju G. Meng; Janet Tien
- Inventors: Xiumin Wu; Yan Wu; Lanlan Yu; Napoleone Ferrara; Wei-Ching Liang; Yu-Ju G. Meng; Janet Tien
- Web page: https://patentgrep.com/patent/US8771685B2

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention concerns antibodies to Bv8 and the uses of same.

## Claims

### Claim 1

An anti-Bv8 antibody comprising a variable domain comprising the following six hypervariable region (HVR) sequences:
(i) HVR-L1 comprising KASQSX1X2YX3X4X5SYMN, wherein X1 is L or V; X2 is D; X3 is S or Y; X4 is G or H; and X5 is D or Y;
(ii) HVR-L2 comprising AASX1X2EX3, wherein X1 is N; X2 is L or R; and X3 is S;
(iii) HVR-L3 comprising QQINEDPFT;
(iv) HVR-H1 comprising GYX1X2X3X4YDMH, wherein X1 is S; X2 is F or L; X3 is T; X4 is D or N;
(v) HVR-H2 comprising YIX1X2YX3GX4TX5YNQKFKG, wherein X1 is H or S; X2 is S; X3 is S; X4 is A or S; X5 is L or T, and
(vi) HVR-H3 comprising DX1NYGEAYAMDY, wherein X1 is S,
or an antigen-binding fragment thereof.

### Claim 2 (depends on 1)

The anti-Bv8 antibody of claim 1, wherein HVR-L1 comprises an amino acid sequence of SEQ ID NO: 61 or 91, HVR-L2 comprises an amino acid sequence of SEQ ID NO: 62 or 92, HVR-L3 comprises an amino acid sequence of SEQ ID NO: 63 or 93, HVR-H1 comprises an amino acid sequence of SEQ ID NO: 64 or 94, HVR-H2 comprises an amino acid sequence of SEQ ID NO: 65 or 95, and HVR-H3 comprises an amino acid sequence of SEQ ID NO: 66 or 96, or an antigen-binding fragment thereof.

### Claim 3 (depends on 2)

The anti-Bv8 antibody of claim 2, wherein the antibody comprises:
(1) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:61;
(2) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:62;
(3) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:63;
(4) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:64;
(5) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:65; and
(6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:66,
or an antigen-binding fragment thereof.

### Claim 4 (depends on 3)

The anti-Bv8 antibody of claim 3 comprising a light chain variable domain comprising SEQ ID NO:7 and the heavy chain variable domain comprising SEQ ID NO:8, or an antigen-binding fragment thereof.

### Claim 5 (depends on 2)

The anti-Bv8 antibody of claim 2, wherein the antibody comprises:
(1) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:91;
(2) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:92;
(3) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:93;
(4) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:94;
(5) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:95; and
(6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:96,
or an antigen-binding fragment thereof.

### Claim 6 (depends on 5)

The anti-Bv8 antibody of claim 5 comprising a light chain variable domain comprising SEQ ID NO: 11 and the heavy chain variable domain comprising SEQ ID NO:12, or an antigen-binding fragment thereof.